| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2544356 | Journal of the American Pharmacists Association | 2007 | 6 Pages |
Abstract
Switching SGAs can increase or decrease cardiovascular risk depending on the clinician's follow-on SGA choice. LDL-C and triglyceride levels decreased significantly among veterans switched from olanzapine to ziprasidone. Switching to quetiapine was associated with a reduction in LDL-C, while switching to risperidone resulted in lower triglyceride levels. Clinicians should use these results when building a patient care plan that includes switching of SGAs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Patrick M. (Doctor of Philosophy Candidate, Lieutenant Colonel), L. Douglas (Research Health Scientist, Professor, Pharmacy Health Care Administration and Associate Dean, Professor), Michael A. (Assistant Chief,